

SELA CHEIFETZ PUBLICATIONS 1980 - 2009

2000 - 2009

47. Jheon A, Bansal AK, Zhu B, Ganss B, **Cheifetz S**, Sodek J. Characterisation of the constitutive over-expression of AJ18 in a novel rat stromal bone marrow cell line (D8-SBMC). *Arch Oral Biol.* 2009 Aug;54(8):705-16.
46. Hwang Q, **Cheifetz S**, Overall CM, McCulloch CA, Sodek J. Bone sialoprotein does not interact with pro-gelatinase A (MMP-2) or mediate MMP-2 activation. *BMC Cancer.* 2009 Apr 22;9:121.
45. Cogan G, Bansal AK, Ibrahim S, Zhu B, Goldberg HA, Ganss B, **Cheifetz S**, Armbruster FP, Sodek J. Analysis of human bone sialoprotein in normal and pathological tissues using a monoclonal antibody (BSP 1.2 mab). *Connect Tissue Res.* 2004;45(1):60-71.
44. Komaki M, Asakura A, Rudnicki MA, Sodek J, **Cheifetz S**. MyoD enhances BMP7-induced osteogenic differentiation of myogenic cell cultures. *J Cell Sci.* 2004 Mar 15;117(Pt 8):1457-68.
43. Jheon AH, Suzuki N, Nishiyama T, **Cheifetz S**, Sodek J, Ganss B. Characterization of the 5'-flanking region of the rat AJ18 gene. *Gene.* 2003 May 22;310:203-13.
42. Jheon A, Chen J, Teo W, Ganss B, Sodek J, **Cheifetz S**. Temporal and spatial expression of a novel zinc finger transcription factor, AJ18, in developing murine skeletal tissues. *J Histochem Cytochem.* 2002 Jul;50(7):973-82.
41. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, **Cheifetz S**. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. *Clin Exp Metastasis.* 2000;18(3):253-60.
40. Jheon AH, Ganss B, **Cheifetz S**, Sodek J. Characterization of a novel KRAB/C2H2 zinc finger transcription factor involved in bone development. *J Biol Chem.* 2001 May 25;276(21):18282-9.

1990 - 1999

39. **Cheifetz S**. BMP receptors in limb and tooth formation. *Crit Rev Oral Biol Med.* 1999;10(2):182-98. Review.
38. Zohar R, **Cheifetz S**, McCulloch CA, Sodek J. Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. *Eur J Oral Sci.* 1998 Jan;106 Suppl 1:401-7.
37. **Cheifetz S**. RNase protection assay for BMP type I receptors. *Eur J Oral Sci.* 1998 Jan;106 Suppl 1:174-8.
36. Ogata Y, Niisato N, Furuyama S, **Cheifetz S**, Kim RH, Sugiya H, Sodek J. Transforming growth factor-beta 1 regulation of bone sialoprotein gene transcription: identification of a TGF-beta activation element in the rat BSP gene promoter. *J Cell Biochem.* 1997 Jun 15;65(4):501-12.

35. Lekic P, Rubbino I, Krasnoshtein F, **Cheifetz S**, McCulloch CA, Tenenbaum H. Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing. *Anat Rec*. 1997 Mar;247(3):329-40.
34. Zohar R, Lee W, Arora P, **Cheifetz S**, McCulloch C, Sodek J. Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. *J Cell Physiol*. 1997 Jan;170(1):88-100.
33. Li IW, **Cheifetz S**, McCulloch CA, Sampath KT, Sodek J. Effects of osteogenic protein-1 (OP-1, BMP-7) on bone matrix protein expression by fetal rat calvarial cells are differentiation stage specific. *J Cell Physiol*. 1996 Oct;169(1):115-25.
32. **Cheifetz S**, Li IW, McCulloch CA, Sampath K, Sodek J. Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-beta 1 on bone formation in vitro. *Connect Tissue Res*. 1996;35(1-4):71-8.
31. Wilkinson ET, **Cheifetz S**, De Grandis SA. Development of competitive PCR and the QPCR system 5000 as a transcription-based screen. *PCR Methods Appl*. 1995 Jun;4(6):363-7.
30. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, **Cheifetz S**, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. *Proc Natl Acad Sci U S A*. 1994 Jun 21;91(13):6002-6.
29. Mathew S, Murty VV, **Cheifetz S**, George D, Massagué J, Chaganti RS. Transforming growth factor receptor gene TGFBR2 maps to human chromosome band 3p22. *Genomics*. 1994 Mar 1;20(1):114-5.
28. Bellón T, Corbí A, Lastres P, Calés C, Cebrián M, Vera S, **Cheifetz S**, Massague J, Letarte M, Bernabéu C. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. *Eur J Immunol*. 1993 Sep;23(9):2340-5.
27. **Cheifetz S**, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. *J Biol Chem*. 1992 Sep 25;267(27):19027-30.
26. Massagué J, Andres J, Attisano L, **Cheifetz S**, López-Casillas F, Ohtsuki M, Wrana JL. TGF-beta receptors. *Mol Reprod Dev*. 1992 Jun;32(2):99-104. Review.
25. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, **Cheifetz S**, Massagué J, Lindahl U, Esko JD. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. *Proc Natl Acad Sci U S A*. 1992 Mar 15;89(6):2267-71.
24. Attisano L, Wrana JL, **Cheifetz S**, Massagué J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. *Cell*. 1992 Jan 10;68(1):97-108.

23. Massagué J, **Cheifetz S**, Laiho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor-beta. *Cancer Surv.* 1992;12:81-103. Review.
22. Wrana JL, Cárcamo J, Attisano L, **Cheifetz S**, Zentella A, López-Casillas F, Massagué J. The type II TGF-beta receptor signals diverse responses in cooperation with the type I receptor. *Cold Spring Harb Symp Quant Biol.* 1992;57:81-6. No abstract available.
21. Andres JL, Rönstrand L, **Cheifetz S**, Massagué J. Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. *J Biol Chem.* 1991 Dec 5;266(34):23282-7.
20. López-Casillas F, **Cheifetz S**, Doody J, Andres JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. *Cell.* 1991 Nov 15;67(4):785-95.
19. **Cheifetz S**, Massagué J. Isoform-specific transforming growth factor-beta binding proteins with membrane attachments sensitive to phosphatidylinositol-specific phospholipase C. *J Biol Chem.* 1991 Nov 5;266(31):20767-72.
18. **Cheifetz S**, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massagué J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. *J Biol Chem.* 1990 Nov 25;265(33):20533-8.
17. Massagué J, **Cheifetz S**, Boyd FT, Andres JL. TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties. *Ann N Y Acad Sci.* 1990;593:59-72. Review. No abstract available.
16. Boyd FT, **Cheifetz S**, Andres J, Laiho M, Massagué J. Transforming growth factor-beta receptors and binding proteoglycans. *J Cell Sci Suppl.* 1990;13:131-8. Review.

1980 - 1989

15. Andres JL, Stanley K, **Cheifetz S**, Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. *J Cell Biol.* 1989 Dec;109(6 Pt 1):3137-45.
14. **Cheifetz S**, Massagué J. Transforming growth factor-beta (TGF-beta) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. *J Biol Chem.* 1989 Jul 15;264(20):12025-8.
13. **Cheifetz S**, Ling N, Guillemin R, Massagué J. A surface component on GH3 pituitary cells that recognizes transforming growth factor-beta, activin, and inhibin. *J Biol Chem.* 1988 Nov 25;263(33):17225-8.
12. **Cheifetz S**, Andres JL, Massagué J. The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor. *J Biol Chem.* 1988 Nov 15;263(32):16984-91.

11. **Cheifetz S**, Bassols A, Stanley K, Ohta M, Greenberger J, Massagué J. Heterodimeric transforming growth factor beta. Biological properties and interaction with three types of cell surface receptors. *J Biol Chem*. 1988 Aug 5;263(22):10783-9.
10. Kimchi A, Wang XF, Weinberg RA, **Cheifetz S**, Massagué J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. *Science*. 1988 Apr 8;240(4849):196-9.
9. **Cheifetz S**, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massagué J. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. *Cell*. 1987 Feb 13;48(3):409-15.
8. Massagué J, **Cheifetz S**, Imitola JA, Boyd FT. Multiple type-beta transforming growth factors and their receptors. *J Cell Physiol Suppl*. 1987;Suppl 5:43-7. Review.
7. Massagué J, **Cheifetz S**, Endo T, Nadal-Ginard B. Type beta transforming growth factor is an inhibitor of myogenic differentiation. *Proc Natl Acad Sci U S A*. 1986 Nov;83(21):8206-10.
6. **Cheifetz S**, Like B, Massagué J. Cellular distribution of type I and type II receptors for transforming growth factor-beta. *J Biol Chem*. 1986 Jul 25;261(21):9972-8.
5. **Cheifetz S**, Boggs JM, Moscarello MA. Increase in vesicle permeability mediated by myelin basic protein: effect of phosphorylation of basic protein. *Biochemistry*. 1985 Sep 10;24(19):5170-5.
4. **Cheifetz S**, Moscarello MA. Effect of bovine basic protein charge microheterogeneity on protein-induced aggregation of unilamellar vesicles containing a mixture of acidic and neutral phospholipids. *Biochemistry*. 1985 Apr 9;24(8):1909-14.
3. **Cheifetz S**, Moscarello MA, Deber CM. NMR investigation of the charge isomers of bovine myelin basic protein. *Arch Biochem Biophys*. 1984 Aug 15;233(1):151-60.
2. Deber CM, **Cheifetz S**, Moscarello MA. Microheterogeneity of bovine myelin basic protein studied by nuclear magnetic resonance spectroscopy. *Biopolymers*. 1983 Jan;22(1):377-80. No abstract available.
1. **Cheifetz S**, Warsh JJ. Occurrence and distribution of 5-hydroxytryptophol in the rat. *J Neurochem*. 1980 May;34(5):1093-9. No abstract available.